The guide to GLP-1 prepayment explains why the duration of a payment commitment can differ from the duration of treatment. In this small Japanese cohort, a policy set the stopping point [1]. Much of the other evidence comes from randomized withdrawal trials or databases that capture people who stopped for different reasons.
During treatment, mean weight change reached a partial plateau across months 10 to 14 at -16.3%, -16.1% and -15.5%, and stood at -16.0% at the month-16 endpoint. Then the cap took effect. Of the patients followed past it, 21 of 22 had regained weight within two months and 10 of 12 within six.
Relative to the baseline six months before treatment, the study reported mean changes of −14.4% at month 16 and −7.0% at month 22. Follow-up at month 22 included 12 patients. The authors offer this as a basis for examining whether a mandated stop is compatible with obesity being a chronic condition, which is a careful way of putting a pointed question.
The mandated waiting period produced its own finding. During the required six-month lifestyle phase before any drug was allowed, the post-surgery rescue cohort gained weight (+2.28 kg on average, with 69% gaining) while the primary cohort stayed roughly stable (-0.65 kg, p = 0.004). The groups differed in treatment history. The separate guide to GLP-1 prior authorization describes the delays reported by patients seeking coverage in the United States.
For a self-pay buyer in a market with no such rule, the transferable point is about planning rather than policy. A fixed-term plan or prepaid supply can end before you have a plan for continuing care. Discuss continuity with your prescriber before committing to a term. Pricing a course as a finite purchase and pricing it as an ongoing one are different decisions, as why falling prices and annual plans do not mix sets out.